Article

Neuromedin B receptor antagonist suppresses tumor angiogenesis and tumor growth in vitro and in vivo.

School of Dentistry, Pusan National University, Yangsan 626-870, South Korea.
Cancer letters (impact factor: 4.86). 08/2011; 312(1):117-27. DOI:10.1016/j.canlet.2011.08.014 pp.117-27
Source: PubMed

ABSTRACT Neuromedin B (NMB), a member of the mammalian bombesin-like peptide family, and its receptor were aberrantly expressed in vascularized solid tumors. Here, the NMB receptor (NMB-R) antagonist PD168368 specifically inhibited both NMB-induced in vivo and in vitro angiogenesis. In addition, PD168368 showed growth inhibitory effects on MDA-MB-231 breast cancer cells by inducing cell cycle arrest and apoptosis. Furthermore, PD168368 effectively suppressed tumor growth in a xenograft model of breast tumor in vivo. Overall, NMB-R antagonist exhibited a significant antitumor activity by simultaneously inhibiting neovascularization and cancer cell growth, thereby suggesting that NMB-R could be a potential therapeutic target for cancer treatment.

0 0
 · 
0 Bookmarks
 · 
39 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

apoptosis
 
cancer cell growth
 
cancer treatment
 
growth inhibitory effects
 
inducing cell cycle arrest
 
MDA-MB-231 breast cancer cells
 
potential therapeutic target
 
significant antitumor activity
 
vascularized solid tumors
 
vitro angiogenesis
 
xenograft model